{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:42:44Z","timestamp":1792032164161,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40263-016-0311-1","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T08:21:22Z","timestamp":1455610882000},"page":"149-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Worldwide Differences in Regulations of Clozapine Use"],"prefix":"10.1007","volume":"30","author":[{"given":"Jimmi","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petru","family":"Ifteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishiro","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tao","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F. J.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,16]]},"reference":[{"issue":"Suppl 12","key":"311_CR1","first-page":"22","volume":"60","author":"H Hippius","year":"1999","unstructured":"Hippius H. A historical perspective of clozapine. J Clin Psychiatry. 1999;60(Suppl 12):22\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"311_CR2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0447.1977.tb00224.x","volume":"56","author":"HA Amsler","year":"1977","unstructured":"Amsler HA, Teerenhovi L, Barth E, Harjula K, Vuopio P. Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic. Acta Psychiatr Scand. 1977;56(4):241\u20138.","journal-title":"Acta Psychiatr Scand"},{"issue":"Suppl 3","key":"311_CR3","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5\u00a0years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl 3):3\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"311_CR4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789\u201396.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"311_CR5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00213-004-1940-5","volume":"177","author":"DM Weiner","year":"2004","unstructured":"Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology. 2004;177(1\u20132):207\u201316.","journal-title":"Psychopharmacology"},{"issue":"10","key":"311_CR6","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1176\/appi.ajp.162.10.1984-a","volume":"162","author":"P Seeman","year":"2005","unstructured":"Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry. 2005;162(10):1984\u20135.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"311_CR7","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1176\/appi.ajp.161.9.1620","volume":"161","author":"J Tauscher","year":"2004","unstructured":"Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry. 2004;161(9):1620\u20135.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"311_CR8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","volume":"156","author":"S Kapur","year":"1999","unstructured":"Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156(2):286\u201393.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"311_CR9","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/S0014-2999(97)81951-6","volume":"338","author":"H Rollema","year":"1997","unstructured":"Rollema H, Lu Y, Schmidt AW, Zorn SH. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol. 1997;338(2):R3\u20135.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"311_CR10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2012.06.020","volume":"140","author":"R Roge","year":"2012","unstructured":"Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012;140(1\u20133):204\u201313.","journal-title":"Schizophr Res"},{"issue":"4\u20135","key":"311_CR11","first-page":"121","volume":"47","author":"SR Veerman","year":"2014","unstructured":"Veerman SR, Schulte PF, de Haan L. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. Pharmacopsychiatry. 2014;47(4\u20135):121\u201330.","journal-title":"Pharmacopsychiatry."},{"issue":"6","key":"311_CR12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","volume":"23","author":"RR Conley","year":"2003","unstructured":"Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol. 2003;23(6):668\u201371.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"311_CR13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003088-200342070-00001","volume":"42","author":"P Schulte","year":"2003","unstructured":"Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42(7):607\u201318.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"311_CR14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e318267b3cd","volume":"32","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol. 2012;32(5):678\u201383.","journal-title":"J Clin Psychopharmacol"},{"key":"311_CR15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1192\/bjp.171.2.125","volume":"171","author":"KJ Aitchison","year":"1997","unstructured":"Aitchison KJ, Kerwin RW. Cost-effectiveness of clozapine. A UK clinic-based study. Br J Psychiatry. 1997;171:125\u201330.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"311_CR16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/10398562.2010.525646","volume":"19","author":"G Malalagama","year":"2011","unstructured":"Malalagama G, Bastiampillai T, Dhillon R. Clozapine use in Australia. Australas Psychiatry. 2011;19(2):175.","journal-title":"Australas Psychiatry."},{"issue":"1","key":"311_CR17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82\u201391.","journal-title":"Arch Gen Psychiatry."},{"issue":"6","key":"311_CR18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/archpsyc.63.6.622","volume":"63","author":"MI Krakowski","year":"2006","unstructured":"Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63(6):622\u20139.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"311_CR19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bdi.12018","volume":"14","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord. 2012;14(8):863\u20139.","journal-title":"Bipolar Disord"},{"key":"311_CR20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jad.2014.04.020","volume":"166","author":"P Ifteni","year":"2014","unstructured":"Ifteni P, Correll CU, Nielsen J, Burtea V, Kane JM, Manu P. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord. 2014;166:168\u201372.","journal-title":"J Affect Disord"},{"key":"311_CR21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","volume":"158","author":"JA Lieberman","year":"1991","unstructured":"Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503\u201310.","journal-title":"Br J Psychiatry"},{"issue":"7","key":"311_CR22","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mds.20051","volume":"19","author":"HH Fernandez","year":"2004","unstructured":"Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord. 2004;19(7):831\u20133.","journal-title":"Mov Disord"},{"issue":"6","key":"311_CR23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","volume":"74","author":"J Nielsen","year":"2013","unstructured":"Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013;74(6):603\u201313 (quiz 13).","journal-title":"J Clin Psychiatry."},{"issue":"5","key":"311_CR24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881110391123","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567\u2013620.","journal-title":"J Psychopharmacol."},{"issue":"5","key":"311_CR25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318\u201378.","journal-title":"World J Biol Psychiatry."},{"key":"311_CR26","unstructured":"Netherlands Clozapine Collaboration Group. Dutch guideline for the use of clozapine. http:\/\/www.clozapinepluswerkgroep.nl\/wp-content\/uploads\/2013\/07\/Guideline-for-the-use-of-Clozapine-2013.pdf . Accessed 6 Jun 2015."},{"key":"311_CR27","unstructured":"NICE. National Health and Care Excellence schizophrenia guideline. 2015. http:\/\/pathways.nice.org.uk\/pathways\/psychosis-and-schizophrenia . Accessed 6 Jun 2015."},{"issue":"6","key":"311_CR28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijlp.2007.09.003","volume":"30","author":"PF Schulte","year":"2007","unstructured":"Schulte PF, Stienen JJ, Bogers J, Cohen D, van Dijk D, Lionarons WH, et al. Compulsory treatment with clozapine: a retrospective long-term cohort study. Int J Law Psychiatry. 2007;30(6):539\u201345.","journal-title":"Int J Law Psychiatry"},{"issue":"4","key":"311_CR29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/acps.12144","volume":"129","author":"TH Andersen","year":"2014","unstructured":"Andersen TH, Kappers D, Sneider B, Uggerby P, Nielsen J. Involuntary treatment of schizophrenia patients 2004\u20132010 in Denmark. Acta Psychiatr Scand. 2014;129(4):312\u20139.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"311_CR30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00004850-200505000-00007","volume":"20","author":"CH Ng","year":"2005","unstructured":"Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20(3):163\u20138.","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"311_CR31","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269881108100320","volume":"24","author":"J Nielsen","year":"2010","unstructured":"Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists\u2019 attitude towards and knowledge of clozapine treatment. J Psychopharmacol. 2010;24(7):965\u201371.","journal-title":"J Psychopharmacol."},{"issue":"2","key":"311_CR32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0269881108089819","volume":"23","author":"C Maccall","year":"2009","unstructured":"Maccall C, Billcliff N, Igbrude W, Natynczuk S, Spencer EP, Flanagan RJ. Clozapine: more than 900\u00a0mg\/day may be needed. J Psychopharmacol. 2009;23(2):206\u201310.","journal-title":"J Psychopharmacol."},{"issue":"6","key":"311_CR33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","volume":"123","author":"J Nielsen","year":"2011","unstructured":"Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123(6):411\u201322.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"311_CR34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71\u201393.","journal-title":"Schizophr Bull"},{"issue":"11","key":"311_CR35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","volume":"22","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol. 2012;22(11):818\u201324.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"311_CR36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481\u20135.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"311_CR37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2753.2008.01032.x","volume":"15","author":"A Wheeler","year":"2009","unstructured":"Wheeler A, Humberstone V, Robinson E, Sheridan J, Joyce P. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. J Eval Clin Pract. 2009;15(3):441\u201350.","journal-title":"J Eval Clin Pract."},{"issue":"1","key":"311_CR38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/acps.12193","volume":"130","author":"S Gee","year":"2014","unstructured":"Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand. 2014;130(1):16\u201324.","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"311_CR39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.euroneuro.2011.10.001","volume":"22","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Thode D, Stenager E, Andersen KO, Sondrup U, Hansen TN, et al. Hematological clozapine monitoring with a point-of-care device: a randomized cross-over trial. Eur Neuropsychopharmacol. 2012;22(6):401\u20135.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"311_CR40","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","volume":"25","author":"LB Zahodne","year":"2008","unstructured":"Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson\u2019s disease: a review. Drugs Aging. 2008;25(8):665\u201382.","journal-title":"Drugs Aging"},{"issue":"10","key":"311_CR41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/archpsyc.1990.01810220061007","volume":"47","author":"JA Lieberman","year":"1990","unstructured":"Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990;47(10):945\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"311_CR42","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/ncomms5757","volume":"5","author":"JI Goldstein","year":"2014","unstructured":"Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, et al. Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. Nat Commun. 2014;5:4757.","journal-title":"Nat Commun."},{"issue":"1","key":"311_CR43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00023210-200721010-00003","volume":"21","author":"E Whiskey","year":"2007","unstructured":"Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25\u201335.","journal-title":"CNS Drugs."},{"issue":"6","key":"311_CR44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00048674.2011.572852","volume":"45","author":"KJ Ronaldson","year":"2011","unstructured":"Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry. 2011;45(6):458\u201365.","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"311_CR45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/acps.12416","volume":"132","author":"KJ Ronaldson","year":"2015","unstructured":"Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 2015;132(4):231\u201340.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"311_CR46","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/acps.12425","volume":"132","author":"O Freudenreich","year":"2015","unstructured":"Freudenreich O. Clozapine-induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand. 2015;132(4):240\u20131.","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"311_CR47","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4088\/JCP.11r06977","volume":"73","author":"D Cohen","year":"2012","unstructured":"Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307\u201312.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"311_CR48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5694\/j.1326-5377.2009.tb02345.x","volume":"190","author":"JJ Layland","year":"2009","unstructured":"Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust. 2009;190(4):190\u20132.","journal-title":"Med J Aust"},{"issue":"5","key":"311_CR49","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","volume":"69","author":"SE Palmer","year":"2008","unstructured":"Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69(5):759\u201368.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"311_CR50","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/schbul\/sbq137","volume":"38","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophrenia Bull. 2012;38(3):592\u20138.","journal-title":"Schizophrenia Bull."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0311-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0311-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0311-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T11:27:45Z","timestamp":1718364465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0311-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["311"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0311-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}